Nilotinib Viatris (Nilotinib)

Nilotinib blocks the BCR‑ABL tyrosine‑kinase enzyme that drives the growth of leukemic cells. By binding to the ATP‑binding pocket of the enzyme, it stops downstream signaling, leading to reduced proliferation and increased apoptosis of the malignant clone.

The exact dose and dosing schedule are determined by the prescribing physician based on the patient’s clinical condition, prior therapies, and laboratory parameters. Patients should follow the prescriber’s instructions precisely.

Safety data for nilotinib in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and breastfeeding is not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor offering higher potency and a different safety profile compared with first‑generation agents like imatinib. It may be preferred after imatinib failure or intolerance, but the choice depends on individual patient factors and physician judgment.

Nilotinib tablets should be stored at room temperature, below 25 °C, in the original container to protect from moisture and light. Keep out of reach of children and do not store in humid or excessively hot environments.

Nilotinib is taken orally, usually twice daily on an empty stomach (at least one hour before or two hours after a meal). Tablets should be swallowed whole with water and not crushed or chewed.

Serious risks include cardiovascular events such as myocardial infarction, QT‑interval prolongation leading to arrhythmias, severe liver injury, and pancreatitis. Patients should be monitored regularly for these conditions and advised to report any concerning symptoms promptly.

Nilotinib is contraindicated in patients with known hypersensitivity to the drug, those with a history of significant QT prolongation, uncontrolled cardiac disease, or severe hepatic impairment. It should also be avoided in patients taking strong CYP3A4 inhibitors or other QT‑prolonging medications without careful supervision.